Cabergoline is a long-acting ergoline dopamine D2-receptor agonist used to treat hyperprolactinaemia and Parkinson's disease, and as adjunct therapy to suppress lactation. Simson Pharma's Cabergoline reference standard and impurities support stability-indicating testing for this potent but low-dose dopamine agonist.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Cabergoline Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.